To a far greater extent than the vaccines from Pfizer-BioNTech and Moderna, AstraZenecaâs vaccine has been the workhorse of the effort to vaccinate poorer countries, many of which are facing severe vaccine shortages. About 1.1 billion AstraZeneca doses had reached low- and lower-middle income countries as of around the end of October
